isn't nevaxar further behind though?
Phase 3 trials have not commenced for it yet.
Also considering Bayer could effectively buy into this technology and own the only 2 post risection liver cancer drugs, I would not discount this yet.
Charts are looking bearish bigtime.....
I reckon that extremely price sensitive announcements are coming out this half and it is a good time to capitalise.
Won't be buying yet.....but soon.
TheGimp
- Forums
- ASX - By Stock
- broker report says sell with valuation 1.50
isn't nevaxar further behind though?Phase 3 trials have not...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)